Thromb Haemost 2006; 96(03): 239-241
DOI: 10.1160/TH06-08-0443
Theme Issue Editorial Focus
Schattauer GmbH

Emerging themes in the treatment of venous thromboembolism

Jeffrey I. Weitz
1   Departments of Medicine and Biochemistry and Medical Sciences, McMaster University and Henderson Research Centre, Hamilton, Ontario, Canada
› Author Affiliations
Further Information

Publication History

Received 11 August 2006

Accepted 11 August 2006

Publication Date:
30 November 2017 (online)

 

 
  • References

  • 1 Heit JA. The epidemiology of venous thromboembolism in the community: implications for prevention and management. J Thromb Thrombolysis 2006; 21: 23-9.
  • 2 Stein PD, Beemath A, Olson RE. Obesity asa risk factor in venous thromboembolism. Am J Med 2005; 118: 978-80.
  • 3 Abdollahi M, Cushman M, Rosendaal FR. Obesity: risk of venous thrombosis and the interaction with coagulation factor levels and oral contraceptive use. Thromb Haemost 2003; 89: 493-8.
  • 4 Ogden CL, Carroll MD, Curtin LR. et al. Prevalence of overweight and obesity in the United States, 1999–2004. J Am Med Assoc 2006; 295: 1549-55.
  • 5 Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. A controlled trial. Lancet 1960; 01: 1309-12.
  • 6 Hull RD, Raskob GE, Hirsh J. et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximalvein thrombosis. N Engl J Med 1986; 315: 1109-14.
  • 7 Douketis JD, Kearon C, Bates S. et al. Risk of fatal pulmonary embolism in patients with treated venous thromboembolism. J Am Med Assoc 1998; 279: 458-62.
  • 8 Becattini C, Agnelli G, Emmerich J. et al. Initial treatment of venous thromboembolism. Thromb Haemost 2006; 96: 242-50.
  • 9 Bates SM, Weitz JI. The status of new anticoagulants. Br J Haematol 2006; 134: 3-19.
  • 10 Augustino P, Ouriel K. Invasive approaches to treatment of venous thromboembolism. Circulation 2004; 110 (Suppl. 01) I27-34.
  • 11 Comerota AJ, Throm RC, Mathias SD. et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg 2000; 32: 130-7.
  • 12 Leacche M, Unic D, Goldhaber SZ. et al. Modern surgical treatment of massive pulmonary embolism: results in 47 consecutive patients after rapid diagnosis and aggressive surgical approach. J Thorac Cardiovasc Surg 2005; 129: 1018-23.
  • 13 Goldhaber SZ. Acute pulmonary embolism: risk stratification. Pathophysiol Haemost Thromb 2006; 35: 153-6.
  • 14 Emmerich J, Meyer G, Decousus H. et al. Role of fibrinolysis and interventional therapy for acute venous thromboembolism. Thromb Haemost 2006; 96: 251-7.
  • 15 Kearon C. Long-term management of patients after venous thromboembolism. Circulation 2004; 110 (Suppl. 01) I10-8.
  • 16 White RH, Dager WE, Zhou H. et al. Racial and gender differences in the incidence of recurrent venous thromboembolism. Thromb Haemost 2006; 96: 267-73.
  • 17 Buller HR, Agnelli G, Hull RD. et al. Antithrombotic therapy for venous thromboembolic disease: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 401S-428S.
  • 18 Schulman S, Ögren M. New concepts in optimal management of anticoagulant therapy for extended treatment of venous thromboembolism. Thromb Haemost 2006; 96: 258-66.
  • 19 Kearon C, Ginsberg JS, Kovacs MJ. et al. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003; 349: 631-9.
  • 20 Palareti G, Legnani C, Cosmi B. et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-8.
  • 21 Cosmi B, Legnani C, Cini M. et al. D-dimer levels in combination with residual venous obstruction and the risk of recurrence after anticoagulation withdrawal for a first idiopathic deep vein thrombosis. Thromb Haemost 2005; 94: 969-74.
  • 22 Weitz JI. Emerging anticoagulants for the treatment of venous thromboembolism. Thromb Haemost 2006; 96: 274-84.
  • 23 Alguel G, Vormittag R, Simanek R. et al. Preeclampsia and pregnancy loss in women with a history of venous thromboembolism and prophylactic low-molecular-weight heparin (LMWH) during pregnancy. Thromb Haemost 2006; 96: 285-9.
  • 24 Robertson L, Wu O, Landhorne P. et al. Thrombophilia in pregnancy: a systematic review. Br J Haematol 2006; 132: 171-96.
  • 25 Gris JC, Mercier E, Quere I. et al. Low-molecularweight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood 2004; 103: 3695-9.
  • 26 Bates SM, Greer IA, Hirsh J. et al. Use of antithrombotic agents during pregnancy: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (Suppl. 03) 627S-644S.